Lunit collabs with AstraZeneca, secures major deal in France Lunit and AstraZeneca have partnered to develop new AI-powered digital pathology solutions that predict non-small cell lung cancer (NSCLC).
Based on a media release, their collaboration aims…
Neurophet sets up China JVMedical imaging AI company Neurophet from South Korea has established a joint venture in China.
It recently signed an exclusive deal with LADO, one of the leading medical software providers in China,…
Alzheimer’s disease (AD) is a global healthcare challenge lacking a simple and affordable detection method. We propose a novel deep learning framework, Eye-AD, to detect Early-onset Alzheimer’s Disease (EOAD) and Mild Cognitive Impairment (MCI)…
Continue Reading
Hexoskin, a Montreal-based digital health and AI company developing medical-grade wearables and algorithms for health monitoring and diagnostics, is very excited to announce today an additional USD $4.2M capital raise to invest in growth,…
Continue Reading
What You Should Know:
– Exer AI, a clinical AI company specializing in musculoskeletal and movement disorders, has announced a collaboration with Mayo Clinic to expand its platform’s capabilities for diagnosing and treating hand and…
Continue Reading
In the ever-changing landscape of healthcare technology, wearable gadgets could potentially prove to be a game changer in the area of neurological disorders, particularly those that present communication barriers. Consider a situation in which…
Continue Reading
AI startup Paige launched a new AI product this week. The New York City-based company unveiled an AI-powered biomarker module that the company says can evaluate more than 505 genes and identify 1,228 molecular…
Continue Reading
Dementia represents a significant global health challenge, with early screening during the preclinical stage being crucial for effective management. Traditional diagnostic biomarkers for Alzheimer’s Disease, the most common form of dementia, are limited by…
Continue Reading
Parkinson’s disease (PD) is a multifactorial neurodegenerative disorder with high prevalence among the elderly, primarily manifested by progressive decline in motor function. The aging global demographic and increased life expectancy have led to a…
Continue Reading
What You Should Know:
– GrayMatters Health (GMH), developer of non-invasive treatments based on proprietary brain biomarkers associated with mental health disorders, today announced it is expanding its U.S. footprint with additional clinics now offering…
Continue Reading
